Want to see ATRA full AI Analyst Report?
Top Page
Atara Biotherapeutics
(NASDAQ:ATRA)
Select Model
Select Model
Rating:42Neutral
Price Target:
$9.50
▲(3.26% Upside)
Action:Reiterated
Date:08/18/26
The score is primarily held down by weak financial performance (sharp TTM revenue decline, return to losses, negative equity, and continued cash burn). Technical indicators also lean bearish (below key moving averages with negative MACD). Valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Regulatory Progress
FDA acceptance advances tabelecleucel into a defined regulatory review with a target action date, creating a concrete path toward potential approval. This could convert Atara’s clinical-stage platform into a partnered commercial opportunity and support future milestone and royalty economics.
Negative Factors
Sharp Revenue Deterioration
The steep TTM revenue decline and return to a sizable loss indicate that recent earnings power has not been sustained. For a clinical-stage company dependent on collaborations and milestones, volatile revenue makes operating performance less predictable and increases reliance on future development outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress
FDA acceptance advances tabelecleucel into a defined regulatory review with a target action date, creating a concrete path toward potential approval. This could convert Atara’s clinical-stage platform into a partnered commercial opportunity and support future milestone and royalty economics.
Read all positive factors
Atara Biotherapeutics (ATRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$86.22M
Dividend YieldN/A
Average Volume (3M)36.95K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue Growth-96.72%
EPS Growth-253.97%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.18
Shares Outstanding10,037,710
10 Day Avg. Volume24,201
30 Day Avg. Volume36,951
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.89
Price to Sales (P/S)1.88
P/FCF Ratio-4.45
Enterprise Value/Market Cap2.48
Enterprise Value/Revenue34.57
Enterprise Value/Gross Profit37.83
Enterprise Value/Ebitda-15.62
Forecast
1Y Price Target
$15.50Price Target Upside68.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$2.82M
Atara Biotherapeutics Business Overview & Revenue Model
Company Description
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments...
How the Company Makes Money
Atara Biotherapeutics primarily generates revenue through collaboration and license arrangements rather than recurring product sales (as a clinical-stage biotech, it generally does not have sustained commercial revenue). Key revenue streams includ...
Atara Biotherapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.19M | 120.77M | 128.94M | 8.57M | 63.57M | 20.34M |
| Gross Profit | 5.66M | 99.56M | 107.93M | -313.00K | -206.42M | -261.66M |
| EBITDA | -13.71M | 38.63M | -75.75M | -266.00M | -222.26M | -330.75M |
| Net Income | -16.69M | 32.69M | -85.40M | -276.13M | -228.30M | -340.14M |
Balance Sheet | ||||||
| Total Assets | 21.02M | 20.23M | 109.10M | 165.50M | 376.42M | 468.13M |
| Cash, Cash Equivalents and Short-Term Investments | 9.87M | 8.48M | 42.50M | 51.73M | 242.82M | 371.07M |
| Total Debt | 9.88M | 52.80M | 43.83M | 57.87M | 71.70M | 28.27M |
| Total Liabilities | 58.02M | 58.74M | 206.38M | 264.74M | 249.78M | 188.51M |
| Stockholders Equity | -37.00M | -38.50M | -97.28M | -99.23M | 126.64M | 279.61M |
Cash Flow | ||||||
| Free Cash Flow | -21.89M | -50.94M | -68.96M | -194.20M | -274.62M | -231.10M |
| Operating Cash Flow | -21.89M | -50.94M | -68.72M | -192.98M | -270.43M | -220.52M |
| Investing Cash Flow | -607.00K | 18.15M | 8.62M | 123.87M | 202.96M | 22.26M |
| Financing Cash Flow | 8.82M | 16.10M | 59.28M | 2.01M | 53.08M | 103.94M |
Atara Biotherapeutics Technical Analysis
Negative
9.20
Price Trends
9.24
Negative
9.32
Negative
7.70
Positive
Market Momentum
-0.01
Positive
42.09
Neutral
34.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Negative. The current price of 9.2 is above the 20-day moving average (MA) of 9.13, below the 50-day MA of 9.24, and above the 200-day MA of 7.70, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.09 is Neutral, neither overbought nor oversold. The STOCH value of 34.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATRA.
Atara Biotherapeutics Risk Analysis
Atara Biotherapeutics disclosed 76 risk factors in its most recent earnings report. Atara Biotherapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atara Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $209.22M | -0.90 | -87.95% | ― | -100.00% | 14.08% | |
46 Neutral | $299.48M | -0.62 | 187.62% | ― | -8.79% | -195.46% | |
45 Neutral | $143.33M | -10.23 | -31.27% | ― | 1.32% | 59.94% | |
42 Neutral | $86.22M | -7.28 | 44.67% | ― | -96.72% | -253.97% | |
40 Underperform | $13.77M | -0.22 | -108.72% | ― | 2.15% | 17.34% |
* Healthcare Sector Average
ATRA
Atara Biotherapeutics
8.59
-7.00
-44.90%
MGNX
MacroGenics
2.25
0.34
17.80%
ZNTL
Zentalis Pharmaceuticals
2.21
0.49
28.49%
SRZN
Surrozen
25.48
11.55
82.91%
TCRX
TScan Therapeutics
0.20
-2.08
-91.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.